InsiderTrades

Form 4 for CBIO CRESCENT BIOPHARMA, INC.

Accepted 2025-12-17 00:00:00 ET · period of report 2025-12-15 · accession 0001628280-25-057678 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-12-17 2025-12-15 CBIO McNeill Jonathan Pres, COO A - Grant — +25.5K 159.7K +19% —
D 2025-12-17 2025-12-15 CBIO McNeill Jonathan Pres, COO A - Grant $0.00 +78.0K 78.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Ordinary Shares 2025-12-15 A A 19,507 — 153,707 D — — (F1) Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.
2 Common Ordinary Shares 2025-12-15 A A 6,000 — 159,707 D — — (F1) Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.
3 Derivative Stock Option (Right to Buy) 2025-12-15 A A 78,029 $0.00 78,029 D $13.21 · — to 2035-12-15 78,029 Ordinary Shares (F2) This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.